Solco Healthcare launches generic of Benicar HCT

CRANBURY, N.J. — Solco Healthcare this week announced the launch of its generics of Daiichi-Sankyo’s Benicar HCT (olmesartan medoxomil and hydrochlorothiazide) tablets. The drug is indicated to treat hypertension to lower blood pressure.

The Food and Drug Administration approved the abbreviated new drug application for Solco Healthcare parent company Prinston Pharmaceutical.

“As one of fastest-growing U.S. generic companies, we are pleased to be the first wave of companies offering a low cost, high quality alternative to patients in the U.S.,” Solco Healthcare president Hai Wang said.

The drug will be available in dosage strengths of 20 mg/12.5 mg, 40 mg/12.5 mg and 40 mg/25 mg. The sales for all three strengths for the 12 months ended December 2016 were $780.1 million.